← All trials
NCT04037566
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2019
- Primary completion
- Aug 31, 2021
- Completion date
- Aug 31, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Xijing HospitalLead sponsor
- Xijing HospitalOverall official - principal investigator
- Xijing HospitalReponsible party - principal investigator
- Xi'An Yufan Biotechnology Co.,LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.